Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03178344
Other study ID # 16-1911a
Secondary ID R01MH111889-01
Status Completed
Phase N/A
First received
Last updated
Start date August 1, 2017
Est. completion date November 4, 2017

Study information

Verified date February 2018
Source University of North Carolina, Chapel Hill
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Transcranial Alternating Current Stimulation (tACS) is one method that has been demonstrated to enhance alpha oscillations in healthy participants by applying weak electrical currents to the scalp to modulate rhythmic brain activity patterns. This study will involve tACS-induced frontal alpha oscillations, EEG recordings, and other physiological and biological measures.


Recruitment information / eligibility

Status Completed
Enrollment 20
Est. completion date November 4, 2017
Est. primary completion date November 4, 2017
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 18 Years to 65 Years
Eligibility Inclusion Criteria:

- Ages 18-65

- Capacity to understand all relevant risks and potential benefits of the study (informed consent)

- Negative pregnancy test for female participants

Exclusion Criteria:

- History of major neurological or psychiatric illness, including epilepsy

- Medication use associated with neurological or psychiatric illnesses

- Currently undergoing counseling or psychotherapy treatment for depression, anxiety, eating disorders, PTSD or other behavioral conditions

- First degree relative (parent, sibling, child) with major neurological or psychiatric illness

- Prior brain surgery

- Major head injury

- Any brain devices/implants (including cochlear implants and aneurysm clips)

- Braids or other hair styling that prevents direct access to the scalp (if removal not possible)

- Skin allergies or very sensitive skin

- Pregnant or nursing females

- Failure to pass a urinary drug test at the first session

- Use of hormonal birth control or supplements in the past two weeks

- Non English speakers

- Cardiovascular disease

Study Design


Related Conditions & MeSH terms


Intervention

Device:
XCSITE100 Stimulator tACS
Transcranial alternating current stimulation (tACS) is a method of noninvasive brain stimulation in which weak electrical current are applied to the scalp in a sine wave pattern to induce cortical oscillations at the frequency at which they are applied.
XCSITE100 Stimulator Sham
The participant will receive up to one minute of tACS stimulation until the stimulation fades. Sham stimulation mimics the skin sensations a participant would experience during a tACS session.

Locations

Country Name City State
United States University of North Carolina Chapel Hill Chapel Hill North Carolina

Sponsors (3)

Lead Sponsor Collaborator
University of North Carolina, Chapel Hill National Institute of Mental Health (NIMH), National Institutes of Health (NIH)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Salivary Alpha Amylase Change after stimulation Before and after 40-minute stimulation at each session.
Primary Salivary Cortisol Change before and after stimulation Before and after 40 minutes of stimulation
Secondary Heart Rate Variability Change in the ratio between the power in low frequency band and the power in high frequency band. As this outcome variable is a ratio between two items that are measured in microvolt^2, the ratio does not have a unit of measure. Before and after 40-minute stimulation at each session.
Secondary Percent Change in Respiration Respiration rate, measured via a belt placed around the participant's abdomen as breaths per second. Before and after 40-minute stimulation at each session.
Secondary Electroencephalogram (EEG) The investigators will compare alpha oscillation power from resting-state EEG recordings before and after stimulation/sham at each session. Before and after 40-minute stimulation at each session.
See also
  Status Clinical Trial Phase
Recruiting NCT06052553 - A Study of TopSpin360 Training Device N/A
Completed NCT05511077 - Biomarkers of Oat Product Intake: The BiOAT Marker Study N/A
Recruiting NCT04632485 - Early Detection of Vascular Dysfunction Using Biomarkers From Lagrangian Carotid Strain Imaging
Completed NCT05931237 - Cranberry Flavan-3-ols Consumption and Gut Microbiota in Healthy Adults N/A
Terminated NCT04556032 - Effects of Ergothioneine on Cognition, Mood, and Sleep in Healthy Adult Men and Women N/A
Completed NCT04527718 - Study of the Safety, Tolerability and Pharmacokinetics of 611 in Adult Healthy Volunteers Phase 1
Completed NCT04065295 - A Study to Test How Well Healthy Men Tolerate Different Doses of BI 1356225 Phase 1
Completed NCT04998695 - Health Effects of Consuming Olive Pomace Oil N/A
Completed NCT04107441 - AX-8 Drug Safety, Tolerability and Plasma Levels in Healthy Subjects Phase 1
Completed NCT01442831 - Evaluate the Absorption, Metabolism, And Excretion Of Orally Administered [14C] TR 701 In Healthy Adult Male Subjects Phase 1
Terminated NCT05934942 - A Study in Healthy Women to Test Whether BI 1358894 Influences the Amount of a Contraceptive in the Blood Phase 1
Recruiting NCT05525845 - Studying the Hedonic and Homeostatic Regulation of Food Intake Using Functional MRI N/A
Completed NCT05515328 - A Study in Healthy Men to Test How BI 685509 is Processed in the Body Phase 1
Completed NCT05030857 - Drug-drug Interaction and Food-effect Study With GLPG4716 and Midazolam in Healthy Subjects Phase 1
Completed NCT04967157 - Cognitive Effects of Citicoline on Attention in Healthy Men and Women N/A
Recruiting NCT04714294 - Evaluate the Safety, Tolerability and Pharmacokinetics Characteristics of HPP737 in Healthy Volunteers Phase 1
Recruiting NCT04494269 - A Study to Evaluate Pharmacokinetics and Safety of Tegoprazan in Subjects With Hepatic Impairment and Healthy Controls Phase 1
Completed NCT04539756 - Writing Activities and Emotions N/A
Recruiting NCT04098510 - Concentration of MitoQ in Human Skeletal Muscle N/A
Completed NCT03308110 - Bioavailability and Food Effect Study of Two Formulations of PF-06650833 Phase 1